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Abstract
Drug discovery and development advances in the last decades allowed to find 
a treatment for many preventable diseases. However, all too often, children are 
excluded from these progresses since most of the new medicines have been discov-
ered and developed for the adult population. Even if paediatricians routinely give 
drugs to children ‘off-label’, researchers have demonstrated that children do not 
respond to medications in the same way as adults. Furthermore, certain specific 
disorders are unique to children or occur in children differently than in adults. 
Besides specifically testing medicines in children in proper clinical studies taking 
into due account the peculiarity of this population, there is a growing recognition 
of the need to develop paediatric medicines having in mind the specificities of this 
vulnerable population. In this chapter, we will provide an overview on the drug 
discovery and development path for children highlighting challenges and new fron-
tiers of each phase from the discovery to the preclinical and clinical development 
as well as we will provide a slightest hint about paediatric biomarkers discovery, 
age-appropriate formulation, pregnancy, and perinatal pharmacology and in silico 
pharmacology. Finally, pricing and reimbursement policies for medicines and new 
and existing research initiatives in the field will be discussed.
Keywords: human development research, paediatric drug discovery, preclinical 
research, juvenile animal models, paediatric pharmacology, paediatric biomarkers, 
age-appropriate formulations, perinatal pharmacology, physiologically-based 
pharmacokinetic (PBPK)
1. Introduction
Even if paediatricians routinely give drugs to children ‘off-label’ (drug not 
specifically approved for use in children), it is known that children respond to drugs 
in a very different way than adults in terms of safety and efficacy [1]. Anatomical, 
physiological and developmental differences between children and adults and 
among children of different ages reflect in changes in absorption, distribution, 
metabolism and excretion (ADME). Moreover, less information is available in 
younger age groups and neonates. Furthermore, while certain specific disorders 
are unique to children, others could be more common in children than adults or 
infrequent in children compared to adults. Notwithstanding, children have been 
excluded from testing of new drugs for many years and for this reason have been 
defined as ‘Therapeutic Orphans’ by Shirkey in 1969 [2].
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The lack of a regulatory framework that obliged to test medications in the pae-
diatric population taking into account the specificities of children and the ethical 
concerns behind resulted in several examples of therapeutic tragedies in paediatric 
patients. A new liquid formulation of the antibiotic sulphanilamide was developed 
in 1938 to allow oral dosing for paediatric patients who could not swallow the tablet 
form. Unluckily, the solvent used to dissolve the active substance was a toxin that 
caused many adverse events with a 30% mortality rate [3]. And again, Thalidomide 
was marketed in Europe in the late 1950s for the treatment of nausea in pregnant 
women causing severe birth defects in thousands of children including severe 
shortening of the extremities, malformations of ears, heart, intestines and other 
structures, depending on the embryologic stage at the time of exposure [4].
These tragedies are just an example of the high risk to which children have been 
exposed for years and have led to the increasing awareness that new medications 
for children should be carefully studied before they could be approved, defining 
the proper requirements and ethical issues to guarantee efficacious and safer drugs 
for children. As a consequence, regulations have been adopted independently in 
the most developed countries, but in accordance with unified guidelines suggested 
by the International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH), an organisation working on 
the harmonisation of pharmaceutical regulatory requirements within the European 
Union (EU), Japan and the United States (US) [5].
The European Paediatric Regulation was adopted in 2006 and entered into force 
in 2007 [6] imposing to pharmaceutical companies developing drugs of potential 
interest for children to prepare a paediatric investigational plan (PIP) to obtain a mar-
keting authorisation for an indication in adults, unless they were granted a product-
specific waiver by the Paediatric Committee of the European Medicines Agency 
(EMA), for example if the indication does not occur in children [7]. The paediatric 
regulation has defined rules concerning the development of medicinal products for 
paediatric use and introduced rewards and incentives for the development of paediat-
ric drugs (i.e. the paediatric-use marketing authorization—PUMA) [5].
In the US, two main acts have complemented each other ruling the evaluation of 
drugs in infants and children and increasing the paediatric clinical studies and drug 
labelling for children: the PREA of 2003 [8] and the BPCA of 2002 [9], both amended 
in the FDAAA of 2007 [10]. A different approach has been taken in Japan, more 
focused on premiums granted to pharmaceutical companies as rewards for developing 
paediatric medicines without a regulatory framework specifically addressing paedi-
atric clinical research. As an effect of these premiums, the price of those drugs is not 
reduced as normally occurred every 2 years in the Japanese system [11].
2. Paediatric diseases
A major challenge in studying paediatric diseases is the relatively low incidence 
rate or uniqueness of some disorders in children. Paediatric diseases may resemble 
those in adults, but considerable differences may also exist with regards to aetiol-
ogy, progression, comorbidities and prognosis [12].
Several cancer types are genetically different in children compared to adults as 
demonstrated by a comprehensive analysis of genetic alterations in a pan-cancer 
cohort including 961 tumours from children, adolescents, and young adults, and 
comprising 24 distinct molecular types of cancer [13]. Epilepsy in children is 
associated with a wide range of congenital or hereditary diseases, while in adults, 
it is associated mainly with strokes and brain tumours [14]. The onset of systemic 
lupus erythematosus (SLE) during childhood is associated with different clinical 
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manifestations and two to three times higher mortality compared to adult-onset 
SLE [15]. Moreover, frequent comorbidities are specific of premature neonates 
including persistent ductus arteriosus, sepsis, intra-ventricular haemorrhage and 
necrotising enterocolitis, and mortality is the highest in premature neonates born 
<28 weeks’ gestation [16, 17].
The above studies provide just some examples of how children and adults can 
be differently affected by similar diseases underling the importance to address 
the drug discovery and development process starting from the specificities of the 
paediatric population.
2.1 Changes occurring during development and age groups
Obviously, childhood is the period of life when the physiological and physical 
changes are the most important and the fastest. Physiological systems and functions 
are immature in neonates at birth with the degree of immaturity depending on 
gestational age. These systems develop progressively and changes can be observed, 
for example, in gastrointestinal motility and function, body composition and size, 
activities of transporters and metabolism enzymes, and renal function. The process 
is dynamic and nonlinear with progressive rapid growth and maturation in the first 
weeks/months of life, and slower thereafter. These developmental changes affect 
drug disposition, as discussed later, with differences among neonates, children, 
adolescents and adults [18, 19].
Therefore, defining the paediatric population is a very complex issue since it rep-
resents an extremely heterogeneous population. To address the peculiarity of each 
age group and to provide guidance for regulatory and clinical matters, the interna-
tional regulation on paediatric clinical trials [20] has described four subsets: pre-
term and term neonates (0–27 days), infants (1–23 months), children (2–11 years) 
and adolescents (12–18 years). In addition, the recently revised EMA guideline 
‘Ethical considerations for clinical trials on medicinal products conducted with 
minors’ issued on September 2017 has further sub-divided the age group 2–18 years 
into pre-schoolers (2–5 years), schoolers (6–9 years) and adolescents (10–18 years) 
[5, 21]. It has to be underlined that this definition, although useful to unify the 
system of rules and law in this field, does not always reflect the maturity of the 
child, which is something that is generally recognised as crucial aspect to be taken 
into account during the conduct of paediatric clinical trials [5].
2.2 Rare diseases
When it comes to talking about paediatric diseases, we cannot exclude the rare 
disease field since many rare diseases are diagnosed during childhood. Rare diseases 
include a very heterogeneous group of disorders, affecting any body system. A 
disease is defined rare if it affects fewer than 1 in 2000 people in Europe and fewer 
than 200,000 people in the United State. A high percentage of rare diseases (about 
80%) affect children, and in 50% of cases, all rare diseases are characterised by 
a childhood-onset with a significant impact on the well-being of the patients and 
families [22–24].
Although rare diseases have by definition a low prevalence, with some having a 
single identified case worldwide, collectively they affect about 6–8% of the human 
population with a number of diseases recognised as rare comprised between 6000 
and 8000 diseases [25].
Despite the high impact they have on the worldwide population, few treatments 
are available on the market. Drug development for rare diseases poses unique scien-
tific and ethical challenges, most of which in common with the obstacles described 
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in this chapter for the paediatric population. Since they affect a small population, 
heterogeneous and widely dispersed, it is more difficult to enrol enough patients in 
clinical studies and pharmaceutical company shows a scarce interest in this field for 
the low return they may have.
Moreover, considering the high incidence and prevalence during the childhood, the 
ethical issue is predominant in this field. And additional challenges may result from 
the frequently progressive, life-limiting or life-threatening nature of these diseases.
As described below, new approaches in all the phases of the drug development 
process may offer valuable solutions to overcome these difficulties in the rare 
diseases as well as paediatric diseases field.
3. Tailored drugs for children
Drug discovery and development path represents the long process starting with 
the identification of new target molecules (discovery phase), going through stud-
ies on microorganisms and animals (preclinical development) and finally testing 
the new medicines in the target population (clinical development) to bring them 
to the market (authorization and commercialization). Considering the differences 
between children and adults above mentioned, a new drug to be used in children 
should be specifically tested in children themselves in controlled clinical studies. 
At the same extent, medicines for children should be developed having in mind the 
specificities of this vulnerable population starting from the very initial phase of 
discovery.
3.1 Drug discovery
In order to make available better medicines for children, it is mandatory to start 
thinking differently from the beginnings of the long process of drug development 
and stop the habit to translate results from adult to children. Even if we cannot 
deny the potentialities and advantages of using existing drugs in alternative ways or 
populations, as the case of repurposed drugs or the use of extrapolation in paediat-
ric drug development, these approaches should be considered complementary to a 
drug discovery tailored to children and not the only way to go.
Drug discovery for children should be focused on specific targets for paediatric 
indications and should not be influenced by the existing knowledge for adults. 
Appropriate preclinical animal and cellular models should be used, and new emer-
gent technologies should be implemented.
The main challenges in the research of novel medications for children come 
from a range of unique characteristics of this population. As highlighted before, 
several paediatric diseases are unique of childhood or differ in children compared 
to adult. Therefore, it is of major importance to increase our understanding of the 
disease mechanism in children and of the human development mechanism relevant 
for paediatric diseases and use this knowledge to favour a proper drug target selec-
tion and validation. For this aim, the availability of adequate disease models, both 
at in vitro and in vivo experimentation level, is a critical factor.
The existing human cell lines are frequently derived from adult sources, making 
them inappropriate as in vitro model of paediatric diseases. Indeed, several studies 
have highlighted the differences existing between adult and foetal/neonatal cells. 
Differences in platelet transcriptome [26] and proteome [27] have been described 
between platelets derived from healthy adults and full-term neonates. Variations 
between neonatal and adult fibroblasts and keratinocytes have been described as prob-
ably associated with improved wound healing during the early neonatal period [28]. 
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Xu et al. provided an overview on the in vitro models used to study paediatric brain 
tumours underlined that in the initial drug screening for new therapies, it is critical 
to use cell lines more closely related to the tumour and organism being studied. The 
authors listed 60 paediatric brain tumour cell lines reported in the literature, of which 
only a small number can be obtained from central repositories such as ATCC [29] or 
Children’s Oncology Group (COG) [30], thus rendering more difficult for the research 
community to have access to the most adequate cell lines [31].
Considering these findings, novel preclinical models should be evaluated as plat-
form for drug discovery for paediatric diseases, such as induced pluripotent stem 
cells (iPSCs) or innovative techniques including organoids and organs-on-a-chip. 
Disease-specific iPSCs represent a promising platform to understand pathologi-
cal progression in patient-derived cells presenting many advantages: iPSCs are an 
unlimited source of patient-specific cells for drug testing and for the development 
of personalised medicine [32]. Advances in human pluripotent stem cell (hPSC) or 
tissue-resident adult stem cell (AdSC) research have led to the possibility to mimic 
any tissue in the human body through three-dimensional (3D) model including 
organoids and organs-on-a-chip that can be used as in vitro screening models [33]. 
However, to confirm the adherence of these in vitro models with their normal coun-
terparts in vivo, we need a much deeper understanding of the physiology of human 
development than what is currently available.
In addition, as regarding the animal models, the number of comprehensive 
studies describing the normal development of different physiological systems and 
processes in laboratory animals from molecular to system levels is very limited, 
and such studies usually do not exist in animal models of paediatric diseases. Thus, 
questions of comparability of developmental stages across species continue to 
create debate. The need to use juvenile animal models will be better discussed in the 
following section.
In addition to the need of developing cellular and animal models more suitable 
to study paediatric diseases and the instruments to work with immature animals, 
all the new emergent technologies should be timely applied to the paediatric drug 
discovery in order to speed up the pharmacological research, including pluripotent 
stem cell, 3D cell cultures, target validation, patient-derived cell assays, micro-
fluidics, high-throughput cell image analysis, non-invasive drug delivery systems 
and devices to measure drug safety or efficacy non-invasively.
3.2 Preclinical development
Commonly, only a small number of compounds identified in the initial discov-
ery phase will pass through to more rigorous preclinical development. Pre-clinical 
studies—in vitro, in vivo, and ex vivo—are essential steps in the drug development 
path to provide detailed information about the pharmacokinetic (PK) and phar-
macodynamics (PD) properties of the selected molecules. The main goal of this 
phase is to improve the understanding of the drug properties in vivo, evaluating 
their efficacy, biodistribution, toxicity involving multiple experts, and competences 
from pharmacologists, drug metabolism specialists, chemists, toxicologists and 
formulation experts.
Drug dosing and response may differ markedly between adults and children for 
many reasons: anatomical and physiological differences between paediatric and 
adult population [34, 35], different diseases or presentation of diseases [36], differ-
ences in PK and/or PD profiles [37], different ‘host’ responses [38] different adverse 
drug reactions [39] and drug formulation.
There are many examples of drugs with a diverse PK profile in children com-
pared to adults as a consequence of a different absorption, distribution, metabolism 
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and excretion (ADME) [40]. The rate and extent of the bioavailability of a drug 
may vary as a consequence of the development changes that occur in absorptive sur-
faces, especially the gastrointestinal tract. Dissimilarities have also been reported 
in drug metabolism, transporters expression, biliary function and renal clearance, 
resulting in differences in drug disposition and elimination [41].
Similarly to PK profile, PD profile is also affected by human development and 
drug targets may vary under developmental control: their level of expression, 
affinity or activity may diverge according to the patient’s age, resulting in variable 
drug responses depending on patients’ age group. This is particularly important 
in younger infants, more vulnerable to drug toxicity and related adverse events by 
modifying drug therapeutic windows [42].
Another aspect to be taken into due account is represented by the effect of the 
ontogeny and genetic variation interactions on drug response, known as pharma-
cogenetics [43]. Several pharmacogenetics studies have indeed demonstrated the 
differences in response to drugs between children and adults [44].
To take into consideration these aspects, age-appropriated technologies and 
models in paediatric drug development should be applied: appropriate cellular 
models, juvenile animal model, administration of sub-pharmacologic doses (micro-
dosing) to evaluate PK in a first-in-paediatric study, modelling and simulations and 
pharmacogenetics biomarkers.
Juvenile animal models should be used to take into due account the specificities 
of the paediatric population as described above and to fill the gap between devel-
opmental and mature toxicity. Indeed, the same drugs can have a different safety 
profile in children compared to adults due to many aspects such as body weight, 
developmental differences in growth and function of target organs, immune system 
maturation and different expression of receptors system. For example, adult models 
of epilepsy cannot be simply applied to the study of paediatric epilepsy and key 
differences exist in human and rodent brain maturation process [45].
Extrapolation of data from adults or studies using adult animals is not always 
adequate to predict these differences in safety profile for paediatric age groups. 
For this aim, ‘Guideline on the need for non-clinical testing in juvenile animals of 
pharmaceuticals for paediatric indications’ has been adopted in January 2008 by 
the EMA. The guidelines recommend the ‘use of juvenile animal models when a 
drug safety cannot be appropriately defined in the intended paediatric age group 
on the basis of human data or previous animal studies’ and provide recommenda-
tion on the ‘timing and utility of juvenile animal studies in relation to phases of 
drug development process’. In particular, the document points out that studies in 
juvenile animals should be performed on a case-by-case basis rather than using 
standardised study protocols and describes the key aspects to take into consid-
eration in the study’s design: age of the animal and duration of the studies, route 
of administration, selection of species, PK and toxicokinetics, dose selection, 
endpoint [46]. Juvenile studies are especially recommended when it has been 
demonstrated that a medicine causes toxicity in adult at the target organ level and/
or to tissues that undergo significant post-natal development (CNS, immune, or 
reproductive systems). As also underlined by Anderson et al., it is important to 
conduct the preclinical experiments in the most appropriate species at the most 
relevant age on the basis of comparability of the specific organ system develop-
ment in question [47]. And many issues have to be considered in juvenile toxicol-
ogy studies: difficulties in the dose administration due to the small size of the 
animals, in blood and tissue sample collection, and in distinguishing direct versus 
latent effects [48].
Therefore, proper animal models should be developed. As an example, Lohi 
et al. described the zebrafish as a model for paediatric diseases, with particular 
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emphasis on haematopoietic and infectious diseases [49]. In this direction, several 
zebrafish models for the study of leukaemia have been developed [50–52].
Preclinical data obtained from juvenile studies, extrapolated assuming a cor-
relation between developmental growth in animals and children, can be linked 
to different information from a variety of data sources using the modelling and 
simulation (M&S) approach.
M&S is a multidisciplinary science, which integrates knowledge about diseases, 
drug characteristics, in vitro, in vivo, and ex vivo data, patient populations and 
clinical trial parameters in order to optimise study design and drug labelling [53]. 
Modelling and simulation tools have long been used in drug development to allow 
a quantitative assessment of age- or growth-related differences in drug effects and 
consequently the potential implications for different paediatric age groups [54]. 
On this basis, software has been created to link in vitro data to in vivo ADME and 
pharmacokinetic/pharmacodynamic (PK/PD) outcomes in order to predict the 
potential clinical complexities prior to human studies [55].
The use of a model-based approach in the paediatric context provides several 
advantages allowing the integration of prior in vitro data and physiologically based 
pharmacokinetic (PBPK) models with pharmacodynamics (PD) models (PBPK-PD 
models) and the optimization of experimental protocols. Finally, this approach 
improves the accuracy and efficiency of data extrapolation and allows the reduction 
in the number of animals per experiment that sometimes may also be replaced by in 
silico experiments.
3.3 Clinical development
Finally, efficacy and safety of the new medicine should be tested in appropriate 
clinical trials. When it comes to the clinical development of a drug, several issues 
related to the peculiarity of the paediatric population have to be faced. Conducting 
a paediatric clinical trial raises several scientific and operational challenges.
First of all, the low prevalence of many paediatric diseases leads to a limited 
number of children affected by each condition. In addition, the ethical issues are 
also to be considered to obtain clinical benefits for children assuring the best pos-
sible protection for these vulnerable subjects. Moreover, considering the heteroge-
neous nature of the paediatric population, the population subsets to be included in a 
study should be chosen with great attention in order to be sure to consider the most 
likely target population for the medicine being tested.
Another issue to be considered in the design of a paediatric clinical trial is the 
lack of tools and/or methods for quantitative and qualitative assessment tailored for 
the paediatric population and its sub-groups (study endpoints, questionnaires and 
scales for the measurement of psychophysical parameters and tools for the assess-
ment of adverse reactions).
The difficulties described above, in testing appropriate drugs in children, 
have brought to an increased use of off-label drugs with high risks for adverse 
safety events and efficacy failures and to a general knowledge gap in paediatric 
research [1].
The US and EU Regulatory agencies foster the drug clinical development 
through regulations and incentives and the increasing number of paediatric trials 
and specific label changes and dosing recommendations.
Ground-breaking methodologies such as innovative trial design, application of 
modelling and simulation and other tools supporting paediatric trials (such as spe-
cific outcomes measures, biomarkers, statistical methods, etc.) can help researchers 
to overcome obstacles faced in planning, initiating and conducting a clinical trial 
involving children.
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For example, to reduce the number of samples required for a study, sparse and 
scavenged sampling approach can be used. Sparse sampling uses a lower number of 
samples per patient compared with traditional PK sampling methods. Scavenged 
sampling consists in the use of residual blood/plasma samples remaining after the 
laboratory tests obtained in the course of medical care. These approaches reduce  
the risk for the child and eliminate the need for vascular punctures specifically for 
the study and, as a consequence, increase the rate of parental consent and the avail-
ability of several samples per infant [56].
Statistical methods, such as the Bayesian design, allow the extrapolation of 
results out of fewer children than in the conventional, fixed-number design, also 
considering evidences in adults [5].
Modelling and simulation approaches allow to successfully predict the optimal 
dosing regimens from the preclinical to the clinical phase [57].
More innovative trial design methods are being developed to overcome the 
limits related to small samples and to the acceptability of the trial. These alterna-
tive approaches, limiting the amount of experimentation in children, represent a 
promising way of ultimately improving paediatric care [58].
3.4 Paediatric biomarkers
A biomarker can be defined as ‘a characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention’ [59].
Biomarkers can be influential in every phase of drug development, from drug 
discovery and preclinical development, through each phase of clinical trials and 
into post-marketing studies. Evaluation and application of biomarkers can be useful 
to refine a drug dose or dose interval, or to select the appropriate population during 
early-phase clinical development of a product [60].
Despite this, the discovery of paediatric biomarkers has been limited and to 
cover the resultant gap, extrapolation, in children, of biomarkers identified and 
employed successfully in adults has become a common practice. However, human 
development impacts almost all factors and systems from organ function to drug 
disposition including the commonly utilised biomarkers that are influenced by 
changes occurring from birth onwards [61]. Therefore, adult biomarkers are not 
always appropriate to a paediatric setting.
A major challenge in the paediatric biomarkers discovery path is the sample 
availability due to the low prevalence of many paediatric diseases. Moreover, 
compared to adults, the paediatric populations is more heterogeneous making 
more difficult to obtain samples for biomarker discovery and validation, with 
the patients often distributed among several centres. Consequently, multicentre 
collaborations are often necessary in order to access sufficiently large study popu-
lations of affected children to generate big enough datasets to adequately power 
research studies [62].
Additional obstacles in children are represented by the difficulty to obtain 
appropriate age-matching control samples in order to minimise the influence that 
age-related changes may have on biomarker discovery and validation. Research on 
healthy children is generally restricted to minimal risk procedures, so although bio-
logical samples like saliva and urine can be relatively easy to obtain, blood samples 
are difficult to obtain in healthy children, particularly in neonates [61].
Moreover, several ethical considerations have to be taken into due account to 
enrol children in a biomarkers study: an effective and simplified consent process, 
long-term retention of samples for future research, the impact of ancillary genetic 
information on family members and predisposition to adult-onset disease [61].
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Current advances in molecular techniques and the speed up of the ‘-omics’ 
technologies (i.e. genomics, transcriptomics, metabolomics and proteomics) have 
provided new tools facilitating the discovery of new biomarkers. The promise of 
omics technologies is considered huge, but translation of these technologies into 
clinical setting has been quite slow especially in the paediatric field.
3.5 Age-appropriate formulation
The effect of age on PK profile, as discussed above, leads to different dosing 
requirements for different age groups. The proper dose administered may vary nearly 
100-fold during childhood as a consequence of the body size and weight increase from 
birth to adulthood [63]. Premature neonates admitted to the hospital can weigh as little 
as 500 g. Moreover, since the maturation process in children is not linear, not always a 
linear relationship exists between a medication dose and body size and/or weight.
The need to have safe and suitable drugs for children has led to the awareness 
that drug formulations tailored to children in all the target age groups is essential. 
Formulation acceptability differs across age groups as children gradually develop their 
cognitive and motor skills, and improve their ability to swallow medications. And taste 
of a drug may be critical to ensure acceptable adherence to paediatric oral formulations.
The ideal formulation for children should have flexible dosage increments and 
minimal excipients, be palatable if given oral, easy and safe to administer, and be 
stable with regard to light, humidity and heat.
Continuous effort in formulation science by academic and paediatric researchers 
and commitment of policy makers and regulators should promote the preparation 
of pharmaceutical formulations for paediatric use, focusing on age tailored forms, 
excipient-related toxicity and safety risks in order to improve acceptability and 
facilitate medication adherence in children.
3.6 Pregnancy and perinatal pharmacology
Up to 80% of women receive at least one medication, over-the-counter (OTC) 
or prescribed, during pregnancy in Europe [64]. The most common drugs used dur-
ing pregnancy are anti-infectives and respiratory drugs [65]. It is recognised that 
medications assumption during pregnancy can represent a risk for the foetus, and 
therefore, medication use is approached with caution by pregnant women and their 
health care providers [66]. Nevertheless, the majority of current therapeutics used 
were never being studied in pregnancy for many reasons. Traditionally, pregnancy 
usually represents an exclusion criterion for phase I testing studies and women of 
childbearing age are usually excluded from clinical trials. Moreover, pharmaceutical 
companies manifest a low interest in the pregnant population since this population 
has more medico-legal risks and ethical concerns and represents a small percentage 
of the patient population that these companies target [66].
Due to the lack of studies involving pregnant women, safety drugs profile is 
usually obtained from either post-marketing surveillance or late-stage retrospective 
studies and efficacy and dosing data can be extrapolated from studies conducted in 
men or non-pregnant women [66].
To foster the availability of more effective and safer obstetrical drugs, a better 
understanding of the changes that occur in the mother, placenta and foetus is essen-
tial and strategies to monitor the therapeutic progress have to be improved [65].
The placenta represents a maternal-foetal interface between the mother and 
baby’s blood and controls exchanges of nutrients, oxygen, wastes and drug transport. 
The process regulating molecular transfer across the placental barrier is poorly under-
stood leading to a lack of precious information for the drug development process.
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Most studies on human placental biology have been conducted on tissue obtained 
after term delivery, or earlier, often from pathological pregnancies at various stages 
of disease, or from ex vivo model system. Less information can be obtained about the 
earlier phases of gestation and the normal development and functions of human pla-
centa [67]. Behind these difficulties in obtaining the tissue, the studies on placenta 
require high level of expertise. To overcome these limitations, some initiatives have 
been undertaken. A 3D in vitro model of human placenta has been developed by a 
research group at the University of Vienna. The 3D model shows self-organisation, 
self-renewal and constant growth capacity and can be also pharmacologically and 
genetically manipulated allowing to study the physiological and pathophysiological 
processes of human placenta [68]. Another attempt to develop a model of human 
placenta has been carried out by the Huh Lab at the University of Pennsylvania, 
which developed the first placenta-on-a-chip to study drug delivery to the placenta 
and preterm birth. It consists of a small block of silicone that contains two overlap-
ping layers of microchannels that are lined with trophoblast cells isolated from the 
outer surface of the placental barrier and separated by a porous membrane [69]. 
These advancements will allow a better understanding of the transport processes 
through the placenta and a better designing of new obstetrician drug.
3.7 In silico pharmacology
In the last decades, advances in computer technology has led to an increase in 
the use of informatics and bioinformatics in biomedical research, moving into an in 
silico era. The introduction of the in silico methods in the drug discovery and devel-
opment has provided the opportunity to simulate every stage of the process, from 
preclinical to clinical, allowing to combine various heterogeneous types of data into 
computer-based pharmacological model.
As an example, in silico methods have been applied successfully in 2003 to drug 
screening when two different research groups found an identical molecule as inhibi-
tor for the TGFb-1 receptor kinase: one using conventional ‘wet-lab’ assays and the 
other using an in silico approach [70]. In parallel, computational methods for drug 
development began to emerge, in order to model the interactions between drugs 
and biological systems [70].
This approach has been translated in paediatrics as a promising method to sup-
port the design of in vivo studies in the early phase of drug development. Johnson 
et al. predict with reasonable accuracy the in vivo drug clearance of 11 drugs that are 
commonly used in neonates, infants and children using in silico prediction methods 
and in particular the Simcyp® software [71]. Using a similar in silico approach, a 
physiologically-based pharmacokinetic model (PBPK) was developed in PK-Sim 
v4.2® to predict lorazepam PK in children as a function of age [72].
The introduction of PBPK modelling software in the field of paediatric drug 
development presents many advantages considering the peculiarities of this popu-
lation. Notwithstanding these approaches could not replace totally the need for 
clinical trials, but they could reduce the amount of clinical trials required in chil-
dren providing a primary exploratory investigation of drug PK, first-time dosing in 
children and study design [71, 72].
4. Pricing and reimbursement policies
The issues linked to the pricing and reimbursement of drugs administered to 
paediatric population are strictly linked to the mechanisms of drug marketing. 
Multiple factors are involved, and alteration of the regulatory environment can 
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rapidly change the drug development pathway chosen by pharmaceutical compa-
nies. At the moment, most of the drugs used for children have a marketing autho-
rization for adults and are used ‘off-label’. No incentives are present for a company 
to perform further studies in a paediatric population if the drug is used and reim-
bursed all the same.
The introduction of regulatory requirements for clinical studies in paediatric 
populations [6, 8, 9] has altered this paradigm for the newest drugs but has not 
changed the situation for the already used ones.
A basic principle for price calculation is the pay for quality-adjusted life years. 
Theoretically, this approach should increase the value of a new paediatric drug, 
but if the same drug is also used for an adult population, the payer would limit the 
price as a larger population is involved. In fact, due to the age stratification of the 
paediatric population, many paediatric pathologies might be considered as a rare 
disease. In fact, due to the facilitation linked to the development of a drug for a rare 
disease, an emerging approach from commercial entities is to develop drugs for the 
smaller paediatric population and to ask for an extension of the marketing licence 
to the adult group only when the licence is going to expire in a reverse approach to 
maximising the revenues for each new drug.
As this is applicable to all small populations, the regulatory agencies are already 
eliminating the rare diseases from the groups receiving extra benefit during the 
marketing authorization process, further complicating the issue.
Overall, due to the personalised medicine approach stratification, there is a 
strong need to increase the public funding during the early stages of drug develop-
ment in order to not only reduce and control the cost of new drug but also encour-
age the development of new class of drugs based on the increased knowledge of the 
human normal and pathological development.
5. New and existing research initiatives in the field
The advancement of innovative technologies in the paediatric pharmacology and 
preclinical phase of drug development will contribute to speed up both the develop-
ment of new medicines for children and the paediatric clinical research. The aware-
ness about the limited application of the innovative technologies in the paediatric 
drug development process and the scarce availability of safer and efficacious drugs 
for children has led, over the last years, to the onset of initiatives and collaborative 
efforts in this field.
At European level, we can cite EnprEMA [73], a network of research networks, 
investigators and centres with recognised expertise in performing paediatric 
clinical studies, which have greatly contributed to increase availability of medi-
cines authorised for use in the paediatric population, according to what foreseen 
in the Paediatric Regulation. The TEDDY Network of Excellence (European 
Network of Excellence for Paediatric Clinical Research) [74], funded within the Sixth 
Framework Programme of the European Commission as Task-force in Europe for 
Drug Development for the Young and recognised as category 1 network member of 
Enpr-EMA, aims to favour adequate health policies and a social awareness on the 
importance of the paediatric medicines across Europe. TEDDY network goal is to 
support the paediatric clinical pharmacology and reduce the current fragmentation 
in the development of medicine in children. In line with this goal, TEDDY set up 
the European Paediatric Medicines Database as a pan-European source of informa-
tion that includes data on paediatric medicines authorised by EMA collected by 
several sources (national authorities, regulatory bodies and pharmaceutical com-
panies). Among other initiatives, we can mention the Conect4Children (C4C) IMI2 
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(Innovative Medicines Initiative 2) project [75] and the PedCRIN project [76]. C4C 
is a European project aimed to implement an infrastructure of clinical sites organ-
ised as a pan-European network to test medicines through well-organised, moni-
tored and evaluated profit and non-profit paediatric clinical trials. PedCRIN project 
is intended to develop tools and actions for paediatric and neonatal trials in order to 
better address the real needs and gaps of the paediatric research community.
Behind the initiatives mentioned above, other actions have been taken to foster 
the early drug discovery and preclinical development phases. In this field, we can 
mention the European Paediatric Translational Research Infrastructures (EPTRI) 
project [77], aimed to design a research infrastructure (RI) completely dedicated 
to paediatrics to be included in the landscape of the ESFRI RIs. EPTRI aims to be 
complementary and fully integrated in the context of the existing RIs providing 
services, competences, expertise in the paediatric drug discovery and develop-
ment. EPTRI will provide support to the paediatric research community through 
its thematic platform: Human Development and Paediatric Medicines Discovery, 
Paediatric Biomarkers and Biosamples, Paediatric Pharmacology, and Paediatric 
Medicines Formulations and Medical Devices. Through them, EPTRI will promote 
a translational approach from the bedside to the bench side, to make available 
more efficacious and safer drugs for children. In the formulation field, it has to be 
mentioned that the European Paediatric Formulation Initiative (EuPFI) [78] is a 
consortium working in a pre-competitive way on paediatric drug formulations and 
aimed to speed up the development of better and safer medicines for children by 
identifying issues and challenges in paediatric formulation development. EuPFI has 
set up the database Safety and Toxicity of Excipients for Paediatrics (STEP) that 
provides updated information on excipients safety and toxicity in children.
To address specifically the rare diseases, the European Joint Programme Rare 
Disease (EJP RD) [79], recently founded by the European Commission, brings over 
130 institutions from 35 countries to create virtuous circle among research, care and 
medical innovation in the rare disease landscape. In particular, the project will improve 
the integration, the efficacy, the development and the social impact of research on 
rare disease and will implement an efficient model of financial support for all types 
of research on RD (fundamental, clinical, epidemiological, social, economic and 
health service), providing support to accelerate the exploitation of research results 
for the benefit of patients. To more specifically focus on the drug development in rare 
diseases, a task force has been created within International Rare Diseases Research 
Consortium(IRDiRC) [80], the Orphan Drug Development Guidebook Taskforce, 
aimed at providing support to academic and industrial drug developers and describing 
the available tools and initiatives specific for rare disease drug development [81].
As described, many initiatives exist as a result of the growing understanding 
that children cannot be considered as small adults, but need to be addressed specifi-
cally in the drug development path. But more efforts and the involvement of the 
national and international policy bodies are still needed to make the development 
of medicines for children a priority.
6. Conclusion
Children represent particular vulnerable subjects and therefore should be pro-
tected and preserved by the risks that a clinical research can entail. However, at the 
same time, higher risks in term of major toxicity and/or reduced efficacy can result 
by the administration of drugs not properly tested and developed for them. Despite 
this, the off-label drug administration is still common in the paediatric population 
and children have been considered for year as the therapeutic orphans due to the 
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recognised lack of medicines specifically targeted for them. Moreover, the enor-
mous progresses and advancements reached in the pharmaceutical field have not 
been applied to the paediatric population at the same extent of the adults.
The gap in the availability of proper medicines for children can be traced back to 
ethical, practical and economic reasons. As discussed in the chapter, the main prac-
tical reasons can be associated with the differences existing in the diseases affecting 
children compared to adults, as well as in the different physiology itself of the chil-
dren compared to adults, the low number of patients affected, the need to take into 
account different age groups and the need to make available appropriate formula-
tions. Moreover, the ethical concerns make more difficult to obtain the parents’ 
consent. In addition, the pharmaceutical companies are not interested in this niche 
market, since they cannot foresee an adequate economic return. Furthermore, more 
challenges have to be faced when considering paediatric rare diseases. Complex 
aetiology, small affected population and subsequently small market size, high cost, 
and possibly low return on investment led to a large gap between basic research and 
patient unmet needs for rare disease drug discovery.
Many initiatives have been taken over the years, also at institutional levels, to 
promote a ‘good research’ in the paediatric field, in order to involve children and at 
the same time preserve them by unnecessary risks. Only increasing our understand-
ing about human development processes and about how these processes impact 
on the onset and progression of diseases will able us to develop specific medicines 
targeted for children. The knowledge of these processes will allow us to transfer in 
the paediatrics all the advancements and innovative technologies nowadays avail-
able in the adults’ pharmacological research. Thus, more efforts are needed in terms 
of capitals, human resources, and technological expertise to speed up both the 
preclinical and clinical drug development in children and make available to children 
new medicines and appropriate treatments.
Conflict of interest
The authors declare that they have no conflict of interest.
Author details
Angelica Intini1,2, Donato Bonifazi1,2* and Giovanni Migliaccio1,2
1 CVBF—Consorzio per Valutazioni Biologiche e Farmacologiche, Bari, Italy
2 TEDDY—European Network of Excellence for Paediatric Clinical Research, Pavia, 
Italy
*Address all correspondence to: ceo@cvbf.net
14
Drug Discovery and Development - New Advances
[1] Corny J et al. Unlicensed and 
off-label drug use in children before 
and after pediatric governmental 
initiatives. Journal of Pediatric 
Pharmacology and Therapeutics. 
2015;20(4):316-328
[2] Shirkey H. Therapeutic 
orphans. The Journal of Pediatrics. 
1968;72(1):119-120
[3] Adams DP. The penicillin 
mystique and the popular press 
(1935-1950). Pharmacy in History. 
1984;26(3):134-142
[4] Ward RM et al. The need for 
pediatric drug development. The 
Journal of Pediatrics. 2018;192:13-21
[5] Chiaruttini G, Mariagrazia F, 
Bonifazi D. Challenges in paediatric 
clinical trials: How to make it feasible. 
In: The Management of Clinical Trials. 
Rijeka: Intech; 2018. pp. 11-33
[6] European Paediatric Regulation of 
2006. Available from: https://www.
ema.europa.eu/en/human-regulatory/
overview/paediatric-medicines/
paediatric-regulation.
[7] Pearson AD et al. 10-year report 
on the European paediatric regulation 
and its impact on new drugs for 
children’s cancers. The Lancet Oncology. 
2018;19(3):285-287
[8] 108th US Congress. Pediatric 
Research Equity Act of 2003. Available 
from: https://www.congress.gov/108/
plaws/publ155/PLAW-108publ155.pdf 
[Accessed: December 3, 2003]
[9] 107th US Congress. Best 
Pharmaceuticals for Children Act. 
Available from: https://www.congress.
gov/107/crpt/srpt79/CRPT-107srpt79.
pdf [Accessed: October 3, 2001]
[10] Congress of the United States of 
America. Food and Drug Administration 
Amendments Act of 2007. Available 
from: https://www.fda.gov/downloads/
Drugs/DevelopmentApproval Process/
DevelopmentResources/UCM049870.
pdf [Accessed: January 4, 2007]
[11] Tsukamoto K et al. Improvement of 
pediatric drug development: Regulatory 
and practical frameworks. Clinical 
Therapeutics. 2016;38(3):574-581
[12] Kearns GL. Selecting the proper 
pediatric dose: It is more than size that 
matters. Clinical Pharmacology and 
Therapeutics. 2015;98(3):238-240
[13] Grobner SN et al. The landscape of 
genomic alterations across childhood 
cancers. Nature. 2018;555(7696):321-327
[14] Camfield P, Camfield C. Incidence, 
prevalence and aetiology of seizures 
and epilepsy in children. Epileptic 
Disorders. 2015;17(2):117-123
[15] Mina R, Brunner HI. Update 
on differences between childhood-
onset and adult-onset systemic lupus 
erythematosus. Arthritis Research & 
Therapy. 2013;15(4):218
[16] Polin RA et al. Surfactant 
replacement therapy for preterm and 
term neonates with respiratory distress. 
Pediatrics. 2014;133(1):156-163
[17] Shapiro-Mendoza CK, Lackritz EM.  
Epidemiology of late and moderate 
preterm birth. Seminars in Fetal & 
Neonatal Medicine. 2012;17(3):120-125
[18] Done AK. Developmental 
pharmacology. Clinical Pharmacology 
and Therapeutics. 1964;5:432-479
[19] Samardzic J, Allegaert K, Bajcetic M.  
Developmental pharmacology: A 
moving target. International Journal of 
Pharmaceutics. 2015;492(1-2):335-337
[20] ICH. E11—Clinical Investigation 
of Medicinal Products in the Paediatric 
References
15
Challenges and New Frontiers in the Paediatric Drug Discovery and Development
DOI: http://dx.doi.org/10.5772/intechopen.85635
Population. Available from: http://www.
ich.org/fileadmin/Public_Web_Site/
ICH_Products/Guidelines/Efficacy/E11/
Step4/E11_Guideline.pdf [Accessed: 
July 19, 2010]
[21] EudraLex. Ethical Considerations 
for Clinical Trials on Medicinal Products 
Conducted with Minors, Revision 1. 
Available from: https://ec.europa.eu/
health/sites/health/files/files/eudralex/
vol-10/2017_09_18_ethical_consid_ct_
with_minors.pdf [Accessed: September 
17, 2017]
[22] Baumbusch J, Mayer S, Sloan-Yip I.  
Alone in a crowd? Parents of children 
with rare diseases’ experiences of 
navigating the healthcare system. 
Journal of Genetic Counseling. 2018. 
DOI: 10.1007/s10897-018-0294-9
[23] Dodge JA et al. The importance of 
rare diseases: From the gene to society. 
Archives of Disease in Childhood. 
2011;96(9):791-792
[24] Zurynski Y et al. Rare childhood 
diseases: How should we respond? 
Archives of Disease in Childhood. 
2008;93(12):1071-1074
[25] Dawkins HJS et al. Progress in rare 
diseases research 2010-2016: An IRDiRC 
perspective. Clinical and Translational 
Science. 2018;11(1):11-20
[26] Caparros-Perez E et al. 
Comprehensive comparison of 
neonate and adult human platelet 
transcriptomes. PLoS One. 
2017;12(8):e0183042
[27] Stokhuijzen E et al. Differences 
between platelets derived from neonatal 
cord blood and adult peripheral 
blood assessed by mass spectrometry. 
Journal of Proteome Research. 
2017;16(10):3567-3575
[28] Mateu R et al. Functional 
differences between neonatal and adult 
fibroblasts and keratinocytes: Donor 
age affects epithelial-mesenchymal 
crosstalk in vitro. International 
Journal of Molecular Medicine. 
2016;38(4):1063-1074
[29] ATCC Cell Lines. Available from: 
http://www.lgcstandards-atcc.org/
[30] Childhood Cancer Repository. 
Available from: https://www.cccells.org/
[31] Xu J et al. Pediatric brain tumor cell 
lines. Journal of Cellular Biochemistry. 
2015;116(2):218-224
[32] Hung SSC et al. Drug discovery 
using induced pluripotent stem cell 
models of neurodegenerative and ocular 
diseases. Pharmacology & Therapeutics. 
2017;177:32-43
[33] Ebert AD, Liang P, Wu JC. Induced 
pluripotent stem cells as a disease 
modeling and drug screening 
platform. Journal of Cardiovascular 
Pharmacology. 2012;60(4):408-416
[34] Bowles A et al. Specific aspects 
of gastro-intestinal transit in 
children for drug delivery design. 
International Journal of Pharmaceutics. 
2010;395(1-2):37-43
[35] Kaye JL. Review of paediatric 
gastrointestinal physiology data relevant 
to oral drug delivery. International 
Journal of Clinical Pharmacy. 
2011;33(1):20-24
[36] Smith ML. Neuropsychology in 
epilepsy: Children are not small adults. 
Epilepsia. 2010;51(Suppl 1):68-69
[37] O’Hara K. Paediatric 
pharmacokinetics and drug 
doses. Australian Prescriber. 
2016;39(6):208-210
[38] Hijiya N et al. Pediatric chronic 
myeloid leukemia is a unique disease 
that requires a different approach. 
Blood. 2016;127(4):392-399
[39] Priyadharsini R et al. A study of 
adverse drug reactions in pediatric 
patients. Journal of Pharmacology 
Drug Discovery and Development - New Advances
16
and Pharmacotherapeutics. 
2011;2(4):277-280
[40] Batchelor HK, Marriott JF.  
Paediatric pharmacokinetics: 
Key considerations. British 
Journal of Clinical Pharmacology. 
2015;79(3):395-404
[41] Fernandez E et al. Factors and 
mechanisms for pharmacokinetic 
differences between pediatric 
population and adults. Pharmaceutics. 
2011;3(1):53-72
[42] Mulla H. Understanding 
developmental pharmacodynamics: 
Importance for drug development and 
clinical practice. Paediatric Drugs. 
2010;12(4):223-233
[43] Vanakker OM, De Paepe A.  
Pharmacogenomics in children: 
Advantages and challenges of next 
generation sequencing applications. 
International Journal of Pediatrics. 
2013;2013:136524
[44] Neville KA et al. Developmental 
pharmacogenomics. Paediatric 
Anaesthesia. 2011;21(3):255-265
[45] Auvin S et al. Novel animal 
models of pediatric epilepsy. 
Neurotherapeutics. 2012;9(2):245-261
[46] Guideline on the Need for Non-
clinical Testing in Juvenile Animals 
of Pharmaceuticals for Paediatric 
Indications. 2005. Available from: 
https://www.ema.europa.eu/
documents/scientific-guideline/
guideline-need-non-clinical-testing-
juvenile-animals-pharmaceuticals-
paediatric-indications_en.pdf
[47] Anderson T et al. Comparative 
juvenile safety testing of new 
therapeutic candidates: Relevance of 
laboratory animal data to children. 
The Journal of Toxicological Sciences. 
2009;34(Suppl 2):SP209-SP215
[48] Kim NN et al. Points to consider 
in designing and conducting juvenile 
toxicology studies. International Journal 
of Toxicology. 2017;36(4):325-339
[49] Lohi O, Parikka M, Ramet M.  
The zebrafish as a model for 
paediatric diseases. Acta Paediatrica. 
2013;102(2):104-110
[50] Feng H et al. Heat-shock induction 
of T-cell lymphoma/leukaemia 
in conditional Cre/lox-regulated 
transgenic zebrafish. British Journal of 
Haematology. 2007;138(2):169-175
[51] Langenau DM et al. Myc-induced 
T cell leukemia in transgenic zebrafish. 
Science. 2003;299(5608):887-890
[52] Teittinen KJ et al. The zebrafish as 
a tool in leukemia research. Leukemia 
Research. 2012;36(9):1082-1088
[53] Kimko H, Pinheiro J. Model-
based clinical drug development 
in the past, present and future: A 
commentary. British Journal of Clinical 
Pharmacology. 2015;79(1):108-116
[54] Bellanti F, Della Pasqua O.  
Modelling and simulation as research 
tools in paediatric drug development. 
European Journal of Clinical 
Pharmacology. 2011;67(Suppl 1):75-86
[55] Simcyp Simulator. Available from: 
https://www.certara.com/software/
physiologically-based-pharmacokinetic-
modeling-and-simulation/simcyp-simu
lator/?ap%5B0%5D=PKPD&ap%5B1%
5D=PBPK
[56] Laughon MM et al. Innovative 
clinical trial design for pediatric 
therapeutics. Expert Review of Clinical 
Pharmacology. 2011;4(5):643-652
[57] Stockmann C et al. Use of 
modeling and simulation in the 
design and conduct of pediatric 
clinical trials and the optimization 
of individualized dosing regimens. 
17
Challenges and New Frontiers in the Paediatric Drug Discovery and Development
DOI: http://dx.doi.org/10.5772/intechopen.85635
CPT: Pharmacometrics & Systems 
Pharmacology. 2015;4(11):630-640
[58] Baiardi P et al. Innovative 
study design for paediatric clinical 
trials. European Journal of Clinical 
Pharmacology. 2011;67(Suppl 1):109-115
[59] Biomarkers Definitions Working 
Group. Biomarkers and surrogate 
endpoints: Preferred definitions 
and conceptual framework. Clinical 
Pharmacology and Therapeutics. 
2001;69(3):89-95
[60] Bai JP et al. Strategic biomarkers 
for drug development in treating 
rare diseases and diseases in neonates 
and infants. The AAPS Journal. 
2013;15(2):447-454
[61] Goldman J et al. Development of 
biomarkers to optimize pediatric patient 
management: What makes children 
different? Biomarkers in Medicine. 
2011;5(6):781-794
[62] Shores DR, Everett AD. Children as 
biomarker orphans: Progress in the field 
of pediatric biomarkers. The Journal of 
Pediatrics. 2018;193:14-20.e31
[63] European Medicines Agency. 
Committee for Medicinal Products 
for Human Use (CHMP). Reflection 
Paper: Formulations of Choice for the 
Paediatric Population. EMEA/CHMP/
PEG/194810/2005. 2005. Available 
from: https://www.ema.europa.eu/
documents/scientific-guideline/
reflection-paper-formulations-choice-
paediatric-population_en.pdf
[64] Tronnes JN, Lupattelli A, Nordeng 
H. Safety profile of medication 
used during pregnancy: Results of 
a multinational European study. 
Pharmacoepidemiology and Drug 
Safety. 2017;26(7):802-811
[65] Mattison DR, Malek A. Drug 
development for use during pregnancy: 
Impact of the placenta. Expert 
Review of Obstetrics & Gynecology. 
2010;5(4):437-454
[66] Ayad M, Costantine MM.  
Epidemiology of medications use in 
pregnancy. Seminars in Perinatology. 
2015;39(7):508-511
[67] Grigsby PL. Animal models to study 
placental development and function 
throughout normal and dysfunctional 
human pregnancy. Seminars in 
Reproductive Medicine. 2016;34(1):11-16
[68] 3d-Model-of-Human-Placenta. 2018. 
Available from: https://www.meduniwien.
ac.at/web/en/about-us/news/
detailsite/2018/news-im-august-2018/3d-
model-of-human-placenta-developed/
[69] Placenta-on-a-Chip. 2018. Available 
from: http://www.yalescientific.
org/2018/09/placenta-on-a-chip/
[70] Shekhar C. In silico 
pharmacology: Computer-aided 
methods could transform drug 
development. Chemistry & Biology. 
2008;15(5):413-414
[71] Johnson TN, Rostami-Hodjegan A,  
Tucker GT. Prediction of the clearance 
of eleven drugs and associated 
variability in neonates, infants and 
children. Clinical Pharmacokinetics. 
2006;45(9):931-956
[72] Maharaj AR, Barrett JS, Edginton 
AN. A workflow example of PBPK 
modeling to support pediatric research 
and development: Case study with 
lorazepam. The AAPS Journal. 
2013;15(2):455-464
[73] EnprEMA. Available from: 
https://www.ema.europa.eu/en/
partners-networks/networks/european-
network-paediatric-research-european-
medicines-agency-enpr-ema
[74] TEDDY Network of Excellence. 
Available from: https://www.
teddynetwork.net/
Drug Discovery and Development - New Advances
18
[75] Conect4Children (C4C). Available 
from: https://conect4children.org/
[76] Paediatric Clinical Research 
Infrastructure Network (PedCRIN). 
Available from: https://www.ecrin.org/
projects/pedcrin
[77] EPTRI (European Paediatric 
Translational Research Infrastructures). 
Available from: https://eptri.eu/
[78] European Paediatric Formulation 
Initiative (EuPFI). Available from: 
http://www.eupfi.org/
[79] European Joint Programme Rare 
Disease (EJP RD). Available from: 
http://www.ejprarediseases.org/
[80] International Rare Diseases 
Research Consortium (IRDiRC). 
Available from: http://www.irdirc.org/
[81] Orphan Drug Development 
Guidebook Taskforce. Available from: 
http://www.irdirc.org/activities/
task-forces/orphan-drug-development-
guidebook-task-force/
